BOARD OF DIRECTORS
Chairman of the Board, President & CEO
Remi Barbier has served as PTI's President and Chief Executive Officer since he founded the Company in 1998. Prior to PTI, Mr. Barbier helped in the growth or founding of: Exelixis Inc., a functional genomics company; ArQule, a chemistry company; and EnzyMed (now owned by Albany Molecular Research), a chemistry company. Prior to PTI Mr. Barbier served as Chief Operating Officer of Exelixis. Prior to that, he was Vice President of Corporate Development and Clinical Project Manager of Xoma Corporation, a biotechnology company. Mr. Barbier received his undergraduate degree from Oberlin College and his graduate degree from the University of Chicago.Chairman of the Board
Chief Medical & Operating Officer
Dr. Nadav Friedmann joined PTI as Chief Medical and Operating Officer in October 2001 and has served as a director since September 1998. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various leadership positions, with Johnson & Johnson, a healthcare company, including Vice President and Head of Research of J&J Biotechnology Center. Prior to that, Dr. Friedmann was Medical Director of Abbott Laboratories. Dr. Friedmann is a graduate of Albert Einstein College of Medicine, where he received an MD, and of the University of California, San Diego, where he received a PhD degree in Biochemistry.
- Robert Gussin PhD
Dr. Gussin has served as a director since March 2003. Dr. Gussin worked at J&J for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Prior to assuming this role, Dr. Gussin worked at J&J’s McNeil division for 12 years, most recently as Vice President, Research and Development and Vice President, Scientific Affairs. Dr. Gussin served on the Board of Directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.Independent Director
- Michael O'Donnell Esq.
Michael O'Donnell has served as a director since June 1998. Mr. O'Donnell has been a member of the law firm of Morrison & Foerster LLP, PTI's corporate counsel, since 2011. Mr. O'Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life science companies. Previously, Mr. O’Donnell was a member of Wilson Sonsini Goodrich & Rosati. Mr. O'Donnell received a JD degree, cum laude, from Harvard University and a BA degree from Bucknell University, summa cum laude.Independent Director
- Saira Ramasastry
Saira Ramasastry has served as a director since February 2013. Prior to 2013, Ms. Ramasastry was an advisor to the Company. Since 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a life science company advisory business. From 1999 to 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc., an investment banking firm. From 1997 to 1998, she was a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry serves on the Board of Directors of Sangamo Biosciences, Inc. and Innovate Biopharmaceuticals, Inc., each a publicly-held biopharmaceutical company, the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the head of business and sustainability for the European Prevention of Alzheimer’s Dementia (EPAD). She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University, Phi Beta Kappa, as well as an M. Phil. in Management Studies from the University of Cambridge.Independent Director
- Sanford Robertson
Sanford Robertson has served as a director since 1998. Mr. Robertson has been a partner of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens & Company, a technology investment bank sold to BankBoston in 1998. Mr. Robertson was also the founder of Robertson, Colman, Siebel & Weisel, later renamed Montgomery Securities, another technology investment bank. Mr. Robertson is a director of Salesforce.com, a publicly-held provider of enterprise cloud computing applications. Mr. Robertson received his B.A. and M.B.A. degrees with distinction from the University of Michigan.Independent Director
- Patrick Scannon MD, PhD
Dr. Pat Scannon has served as a director since 2007. Dr. Scannon is one of the founders of XOMA. From 2006 to 2016, Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006, Dr. Scannon served as Chief Scientific and Medical Officer of XOMA. Dr. Scannon retired from XOMA and resigned from XOMA’s board of directors in 2016. Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia.Independent Director